靶向微粒体前列腺素E_(2)合酶-1的抗炎药物研究进展  

Research advances in microsomal prostaglandin E_(2) synthase-1 targeted antiinflammatory drugs

作　　者：季爽 陈丽红 JI Shuang;CHEN Lihong(Advanced Institute for Medical Sciences,Dalian Medical University,Dalian 116044,China)

机构地区：[1]大连医科大学医学科学研究院,大连116044

出　　处：《中国药科大学学报》2024年第5期697-707,共11页Journal of China Pharmaceutical University

基　　金：国家自然科学基金项目(No.32071157,No.31900142);辽宁省科技厅博士科研启动基金计划项目(2020-BS-202)。

摘　　要：微粒体前列腺素E_(2)合酶-1(mPGES-1)是介导前列腺素E_2(PGE_2)产生的主要终末合成酶,在炎症性疾病中起着至关重要的作用。与非甾体抗炎药相比,mPGES-1抑制剂在阻断PGE_(2)的产生方面具有更好的特异性和更高的安全性,因此被认为是更具前景的抗炎药物。本文总结了mPGES-1分子在炎症和心血管疾病中的研究现状,系统梳理了mPGES-1抑制剂的研究进展,详细阐述了其在不同炎症性动物模型和炎性疾病中的治疗作用,并探讨了可能存在的挑战,以期为后续抗炎药物的研发提供指引和参考。Microsomal prostaglandin E_(2) synthase 1(mPGES-1),the main terminal synthase of prostaglandin E_(2)(PGE_(2)),plays a crucial role in inflammatory diseases.Compared to non-steroidal anti-inflammatory drugs(NSAIDs),mPGES-1 inhibitors are promising agents for their better specificity and higher safety.This article summarizes the research status of mPGES-1 in inflammation and cardiovascular diseases,systematically reviews the research progress of the development of mPGES-1 inhibitors,elaborates on their therapeutic effects in different inflammation animal models and inflammatory diseases,and discusses the possible existing challenges,aiming to provide some guidance and reference for the subsequent research of anti-inflammatory drugs.

关 键 词：非甾体抗炎药 前列腺素E_(2) MPGES-1 炎症性疾病 

分 类 号：R363[医药卫生—病理学] R965[医药卫生—基础医学]